Fractyl Health announced a first-in-human trial for RJVA-001, targeting T2D and obesity, pending regulatory approval by 2026. Fractyl Health, Inc. has announced the submission of the first module of ...
CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany ...
The transformative impact of artificial intelligence (AI) on clinical research, diagnosis, treatment, and our overall understanding of medicine continues to expand. This collection of in-depth ...
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
Given the volume of materials received in a very short period of time, it is not possible to notify applicants of the status of their application. Applications are evaluated based on the applicants' ...
Glioblastoma remains a highly challenging malignancy with a pronounced tendency for recurrence. The hypoxic microenvironment ...
The cost of care for any patient generally follows a variation of Parkinson’s Law. “The more you have available to give to a patient, the more the patient will receive and that requires us to be ...
A comprehensive search was conducted in PubMed, Web of Science, and OpenAlex for literature published between December 1, 2022, and December 31, 2024. Studies were included if they explicitly ...
Our spotlight call highlights key areas where dedicated clinical research efforts focused on upper gastrointestinal cancers of unmet need can improve patient outcomes.
“Wearables” is a term used for forms of technology that are worn on the body, such as smartwatches or adhesive patches containing sensors, and that perform a useful function for the wearer or a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results